Q-omics provides the consensus-scored GLTP profile across patient tissues and cancer cell-line models. GLTP expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GLTP is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, GLTP protein abundance shows 26,484 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, COAD, and GBM as cancer lineages where GLTP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLTP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLTP survival associations across molecular data types. GLTP RNA expression shows survival associations in the most cancer types (18), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLTP RNA expression–survival associations across cancer types. High GLTP expression shows unfavorable associations in MESO, LIHC, UVM and LAML, but favorable associations in CESC and THCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for GLTP RNA expression.
This table summarizes GLTP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GLTP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLTP shows lower tumor expression in COAD, KIRC, LUAD and KIRP and higher tumor expression in LIHC and LUSC. The COAD box plot shows higher GLTP RNA expression in normal versus tumor tissue (log2 FC = −1.589, t-test p < 0.001).
This table shows molecular features associated with GLTP in patient tissues and cancer cell lines. In patient samples, GLTP shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GLTP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LUNG_NSCLC_LUSC.
